Literature DB >> 21934489

Elevated plasma factor VIII and von Willebrand factor in women with type 2 diabetes: inflammatory reaction, endothelial perturbation or else?

Anna L Soares1, Rashid S Kazmi, Michelle A Borges, Pedro W Rosário, Ana P Fernandes, Marinez O Sousa, Bashir A Lwaleed, Maria G Carvalho.   

Abstract

The association between type 2 diabetes and cardiovascular disease is long recognized. Although perturbations of haemostatic markers have been shown to be associated with macrovascular disease in patients with type 2 diabetes, it is unclear whether these are primarily due to endothelial dysfunction or a result of inflammation. The present study was undertaken to elucidate whether elevated levels of factor VIII (FVIII) and von Willebrand factor (vWF) in women with type 2 diabetes represent endothelial dysfunction, inflammation or an alternate mechanism. Sixty-four women with type 2 diabetes were evaluated using ultrasonography Doppler for carotid intima-media thickness (IMT) and were classified as group A--having no (<1  mm), group B - mild (≥1  mm and no plaque) and group C--moderate (≥1 mm and presence of plaque and stenosis) macrovascular disease. Several haemostatic markers including, FVIII, vWF and fibrinogen were assessed. In addition, thrombomodulin, a marker for endothelial damage, and high-sensitivity C-reactive protein (hsCRP), an inflammatory marker, were also measured. A significant association of elevated FVIII was found in group B and C patients (i.e. patients with IMT ≥1 mm and with plaque). Elevated fibrinogen and vWF levels were also found but confined to group C patients. No significant difference among subgroups was found for any other variable evaluated (hsCRP, thrombomodulin and FVII). In conclusion, plasma FVIII levels are elevated in women with type 2 diabetes and macrovascular disease. It also appears that this is not mediated by inflammation or endothelial injury and is likely to be due to an alternate mechanism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21934489     DOI: 10.1097/MBC.0b013e32834b2fe1

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

Review 1.  Targeting hypercoagulation to alleviate Alzheimer's disease progression in metabolic syndrome.

Authors:  Sana Khan; Soumya Pati; Shailja Singh; Mohd Akhtar; Piush Khare; Saba Khan; Sadat Shafi; Abul Kalam Najmi
Journal:  Int J Obes (Lond)       Date:  2021-10-22       Impact factor: 5.095

2.  Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS).

Authors:  Elizabeth M Kiefer; Qiuhu Shi; Donald R Hoover; Robert Kaplan; Russell Tracy; Michael Augenbraun; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Mardge Cohen; Elizabeth T Golub; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

3.  Hemostatic Abnormality and Associated Factors in Diabetic Patients at Jimma University Specialized Hospital, Jimma, Southwest Ethiopia: A Comparative Cross-sectional Study.

Authors:  Debebe Asrat; Girum Tesfaye; Lealem Gedefaw; Wondimagegn Addisu; Tilahun Yemane
Journal:  Ethiop J Health Sci       Date:  2019-03

Review 4.  The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance.

Authors:  Isabella Russo
Journal:  Scientifica (Cairo)       Date:  2012-08-30

5.  Von Willebrand factor regulation in patients with acute and chronic cerebrovascular disease: a pilot, case-control study.

Authors:  Peter Kraft; Christiane Drechsler; Ignaz Gunreben; Bernhard Nieswandt; Guido Stoll; Peter Ulrich Heuschmann; Christoph Kleinschnitz
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.